---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002727"
form_type: "8-K"
ticker: "LFWD"
cik: "0001607962"
company_name: "Lifeward Ltd."
filed_at: "2026-05-15T12:00:26+00:00"
generated_at: "2026-05-15T12:07:11.452653+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M

## Summary
- Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.
- Net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) in Q1 2025; one-time $4.9M R&D charge.
- Unrestricted cash $11.4M at Mar 31, 2026, up from $2.2M at Dec 31, 2025; $6.5M from Oratech.
- Operating cash burn improved 33% YoY to $3.7M; ReWalk exoskeleton sales up 11% to $1.6M.
- Strategic transaction closed: $10M financing, Oratech acquisition with oral insulin Phase 2 trial.

## SEC filing metadata
- accession: 0001178913-26-002727
- form_type: 8-K
- ticker: LFWD
- cik: 0001607962
- company_name: Lifeward Ltd.
- filed_at: 2026-05-15T12:00:26+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/0001178913-26-002727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/zk2635349.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002727
- JSON: https://secwatch.observer/filing/0001178913-26-002727.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.